2026 Q1
SunRay101 antibody screening expected to be completed in Q1 2026.
Musculoskeletal Regeneration:
Musculoskeletal Regeneration:
From Structural Repair to Functional Reconstruction
From Structural Repair to Functional Reconstruction
- Hundreds of millions of tendon injury patients worldwide face retear rates as high as 20%–94% following surgical repair, with no product currently available that enables true tissue regeneration.
- Existing therapies are limited to suturing or physical therapy, which fail to restore native tendon function, leaving patients with recurrent surgeries and permanent functional loss.
SUNRAY Approach
We have developed the world's first allogeneic tendon stem/progenitor cell (TSPC) product to enter clinical trials. Administered via ultrasound-guided local injection, these cells differentiate into tenocytes and secrete extracellular matrix to achieve functional tendon regeneration. In parallel, our CoJump Sports Medicine Center provides AI-powered precision rehabilitation, forming an integrated "cell transplantation + intelligent rehabilitation" service model.
Indications
Rotator cuff tears, Achilles tendon injuries, tendinopathy, knee osteoarthritis, and beyond.
Clinical Value
Shifting the paradigm from "suturing" to "regeneration," offering tendon injury patients the first curative therapeutic approach that reduces reoperation rates and restores motor function.
Technology Infrastructure
R&D across all four application domains is supported by the following three technology platforms:
Metabolic Disease Therapeutics
Musculoskeletal Regeneration
Regenerative Biomaterials
Smart Health Management
AI De Novo Antibody Platform
Directly generates antibodies against antigen epitopes, reducing R&D costs by 70%
AI Cell Screening Platform
Tens of millions of data points accumulated; participates in industry standard-setting
AI Biomaterial Composite Design Platform
Multi-physics simulation reduces experimental workload by over 50%
Key Milestones
-
-
2026
China's first tendon stem cell IIT clinical trial was approved at the Second Affiliated Hospital of Zhejiang University.
-
2026 Q2
PLLA microspheres have completed enrollment of 240+ patients (Class III medical device).
-
2026
Longevity Clinic to be established in 2026.
